180 related articles for article (PubMed ID: 36218113)
1. [Effects of rituximab on prognosis in myasthenia gravis: A single-center experience from Turkey].
Göl MF; Kara F; Boz M; Mutlu A; Karakullukçu S; Boz C
Ideggyogy Sz; 2022 Sep; 75(9-10):351-359. PubMed ID: 36218113
[TBL] [Abstract][Full Text] [Related]
2. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.
Topakian R; Zimprich F; Iglseder S; Embacher N; Guger M; Stieglbauer K; Langenscheidt D; Rath J; Quasthoff S; Simschitz P; Wanschitz J; Windisch D; Müller P; Oel D; Schustereder G; Einsiedler S; Eggers C; Löscher W
J Neurol; 2019 Mar; 266(3):699-706. PubMed ID: 30649616
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.
Landon-Cardinal O; Friedman D; Guiguet M; Laforêt P; Heming N; Salort-Campana E; Jouen F; Allenbach Y; Boyer O; Chatenoud L; Eymard B; Sharshar T; Benveniste O
J Neuromuscul Dis; 2018; 5(2):241-249. PubMed ID: 29865089
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis.
Li T; Zhang GQ; Li Y; Dong SA; Wang N; Yi M; Qi Y; Zhai H; Yang L; Shi FD; Yang CS
J Clin Neurosci; 2021 Mar; 85():6-12. PubMed ID: 33581791
[TBL] [Abstract][Full Text] [Related]
5. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis.
Marino M; Basile U; Spagni G; Napodano C; Iorio R; Gulli F; Todi L; Provenzano C; Bartoccioni E; Evoli A
Front Immunol; 2020; 11():613. PubMed ID: 32431692
[TBL] [Abstract][Full Text] [Related]
6. Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study.
Litchman T; Roy B; Kumar A; Sharma A; Njike V; Nowak RJ
J Neurol Sci; 2020 Apr; 411():116690. PubMed ID: 32028072
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in AChR subtype of myasthenia gravis: systematic review.
Di Stefano V; Lupica A; Rispoli MG; Di Muzio A; Brighina F; Rodolico C
J Neurol Neurosurg Psychiatry; 2020 Apr; 91(4):392-395. PubMed ID: 32098874
[TBL] [Abstract][Full Text] [Related]
8. Promising efficacy of Low-Dose rituximab in Muscle specific kinase antibody positive Myasthenia Gravis.
Yang X; Zhang W; Chang X; Li Z; Du R; Guo J
Neurosci Lett; 2024 Jan; 818():137561. PubMed ID: 37984485
[TBL] [Abstract][Full Text] [Related]
9. Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.
Du Y; Li C; Hao YF; Zhao C; Yan Q; Yao D; Li L; Zhang W
J Neurol; 2022 Aug; 269(8):4229-4240. PubMed ID: 35243555
[TBL] [Abstract][Full Text] [Related]
10. Clinical features, treatment and prognosis of MuSK antibody-associated myasthenia gravis in Northwest China: a single-centre retrospective cohort study.
Zhao S; Zhang K; Ren K; Lu J; Ma C; Zhao C; Li Z; Guo J
BMC Neurol; 2021 Nov; 21(1):428. PubMed ID: 34732168
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of the safety and efficacy of rituximab in Iranian patients with myasthenia gravis: A single-center experience.
Ziaadini B; Karimi N; Panahi A; Okhovat AA; Fatehi F; Nafissi S
Curr J Neurol; 2022 Apr; 21(2):91-97. PubMed ID: 38011443
[No Abstract] [Full Text] [Related]
12. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.
Hehir MK; Hobson-Webb LD; Benatar M; Barnett C; Silvestri NJ; Howard JF; Howard D; Visser A; Crum BA; Nowak R; Beekman R; Kumar A; Ruzhansky K; Chen IA; Pulley MT; LaBoy SM; Fellman MA; Greene SM; Pasnoor M; Burns TM
Neurology; 2017 Sep; 89(10):1069-1077. PubMed ID: 28801338
[TBL] [Abstract][Full Text] [Related]
13. Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study.
Singh N; Goyal V
J Neurol; 2019 Jul; 266(7):1596-1600. PubMed ID: 30919039
[TBL] [Abstract][Full Text] [Related]
14. No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: A systematic retrospective study involving 67 patients.
Wang L; Wang S; Yang H; Han J; Zhao X; Han S; Zhang Y; Lv J; Zhang J; Li M; Ji Y; Zhou S; He X; Fang H; Yang J; Zhang Y; Zhang Q; Gao P; Gao F
Brain Behav; 2021 Jul; 11(7):e02203. PubMed ID: 34075720
[TBL] [Abstract][Full Text] [Related]
15. Use and monitoring of low dose rituximab in myasthenia gravis.
Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R
J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study.
Dos Santos A; Noury JB; Genestet S; Nadaj-Pakleza A; Cassereau J; Baron C; Videt D; Michel L; Pereon Y; Wiertlewski S; Magot A
Eur J Neurol; 2020 Nov; 27(11):2277-2285. PubMed ID: 32526053
[TBL] [Abstract][Full Text] [Related]
17. Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients.
Zhong H; Lu J; Jing S; Xi J; Yan C; Song J; Luo S; Zhao C
J Neuroimmunol; 2020 Nov; 348():577383. PubMed ID: 32961347
[TBL] [Abstract][Full Text] [Related]
18. Rituximab as a sole steroid-sparing agent in generalized myasthenia gravis: Long-term outcomes.
Kefalopoulou ZM; Veltsista D; Germeni A; Lykouras D; Tsiamaki E; Chroni E
Neurol Sci; 2024 Mar; 45(3):1233-1242. PubMed ID: 37831214
[TBL] [Abstract][Full Text] [Related]
19. Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis.
Jing S; Song Y; Song J; Pang S; Quan C; Zhou L; Huang Y; Lu J; Xi J; Zhao C
J Neuroimmunol; 2017 Oct; 311():14-21. PubMed ID: 28789841
[TBL] [Abstract][Full Text] [Related]
20. Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis.
Clifford KM; Hobson-Webb LD; Benatar M; Burns TM; Barnett C; Silvestri NJ; Howard JF; Visser A; Crum BA; Nowak R; Beekman R; Kumar A; Ruzhansky K; Chen IA; Pulley MT; Laboy SM; Fellman MA; Howard DB; Kolb NA; Greene SM; Pasnoor M; Dimachkie MM; Barohn RJ; Hehir MK
Muscle Nerve; 2019 Apr; 59(4):404-410. PubMed ID: 30575980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
